IPUMP Enhances Compliance in SLIT Treatment
Stallergenes Greer, a global leader in allergy diagnostics and immunotherapy, has announced that it will present compelling findings from its SPEED survey at the upcoming Congrès Francophone d’Allergologie (CFA), the premier French-language congress for allergy specialists, taking place in Paris, France, from April 15 to 18, 2025. The data set to be unveiled underscores the clinical and practical benefits of the company’s innovative digital health tool, iPUMP®, and demonstrates its positive impact on treatment adherence in patients undergoing sublingual liquid allergen immunotherapy (SLIT).
As a frontrunner in personalized allergy therapeutics, Stallergenes Greer has long prioritized solutions that cater to the unique needs of patients and healthcare professionals. With the rapid advancement of connected health technologies, the company has taken a significant step forward by integrating digital innovation into its treatment ecosystem. The iPUMP® connected assistant, developed in collaboration with Aptar Digital Health, plays a central role in this digital transformation by supporting and improving the experience of patients receiving SLIT therapies.
The SPEED Survey: Evaluating iPUMP®’s Real-World Impact
The SPEED survey—an acronym for Sublingual Patient Engagement and Enhanced Dosing—was designed as a two-step observational study aimed at evaluating the effectiveness of iPUMP® in enhancing adherence and observance to SLIT regimens. Conducted over a period of several months, the study tracked a cohort of SLIT patients, measuring their treatment behavior both before and after the implementation of the iPUMP® system.
The results from the SPEED survey reveal a substantial improvement in treatment observance among users of iPUMP®. Patients using the connected assistant demonstrated a 15% increase in adherence compared to those who did not use the device. This improvement is clinically significant, as consistent and accurate adherence to allergen immunotherapy is critical to its long-term effectiveness in managing allergic conditions such as rhinitis, asthma, and other respiratory allergies.
The study also delved into a key demographic group—children aged 5 to 12—where adherence can be particularly challenging due to the need for parental oversight and variable maturity levels. The findings in this age group were especially promising: over a three-month period, parental involvement in treatment administration decreased from 50% to 28%, while the number of children independently managing their treatment increased dramatically from 24% to 58%. These figures indicate that iPUMP® not only empowers pediatric patients but also reduces the caregiving burden on parents.
Further qualitative insights were obtained through parental feedback. A striking 90% of parents reported feeling reassured by the use of iPUMP® in their child’s treatment routine. Perhaps even more importantly, half of these parents said they felt completely at ease with the treatment process when iPUMP® was part of the regimen—compared to just 36% in the control group who managed treatment without the connected device.
A Closer Look at iPUMP®: Seamless Integration of Digital Health
iPUMP® is more than just a dosing tool—it is a comprehensive digital assistant that blends seamlessly into the daily lives of SLIT patients. Developed in partnership with Aptar Digital Health, iPUMP® is a smart device that connects to a mobile application, allowing real-time monitoring, reminders, and user guidance based on the treatment protocol prescribed by the patient’s physician. This alignment with individualized therapy plans is central to the tool’s success.
The device ensures that patients follow the correct dosing technique, maintain the proper frequency, and adhere to the recommended duration of treatment. By providing ongoing support, iPUMP® helps to mitigate common pitfalls in allergen immunotherapy such as missed doses, incorrect administration, or premature discontinuation—factors that can severely compromise the efficacy of SLIT.
In her statement on the SPEED survey results, Elena Rizova, Chief Medical Officer at Stallergenes Greer, emphasized the strategic importance of connected health technologies in modern medicine. “Findings of the SPEED survey underscore the role of connected health solutions in improving both treatment adherence and patient confidence, which are key elements in achieving successful therapeutic outcomes,” Rizova said. “Innovation is at the heart of what we do, and iPUMP®, by catering to the needs expressed by patients and healthcare professionals, meets their expectations and provides a solution to enhance treatment management and overall allergy care.”
Industry Collaboration Driving Better Patient Outcomes
The success of iPUMP® reflects a growing trend within the healthcare industry—one that blends traditional therapeutics with digital enhancements to provide smarter, more adaptive care. This transformation is powered by collaborations like the one between Stallergenes Greer and Aptar Digital Health, which combine pharmaceutical expertise with cutting-edge digital development.
Marcus Bates, Vice President of Business Development and Global Head of Respiratory at Aptar Digital Health, noted the broader implications of the SPEED survey. “The strong results of the SPEED survey pave the way for wider adoption of digital and connected solutions for allergy management,” Bates said. “We believe this will enable new patients to access a simple, easy-to-use solution that can help track adherence and stay engaged to achieve better health outcomes.”
The integration of iPUMP® into clinical practice exemplifies a new paradigm of healthcare—one that is data-informed, behaviorally supportive, and deeply aligned with the needs of end-users. The accessibility and ease of use of the iPUMP® device further encourage its adoption, not just among tech-savvy adults, but also among children, seniors, and individuals managing multiple therapies.
A Commitment to Patient-Centric Innovation
For Stallergenes Greer, the SPEED survey represents more than just a successful product validation—it reinforces the company’s overarching mission to deliver precise, personalized, and patient-focused allergy care. By continuing to invest in innovative tools like iPUMP®, the company is helping to redefine what effective allergy management looks like in the 21st century.
As digital health tools become increasingly embedded in therapeutic strategies, Stallergenes Greer’s leadership in this area positions it at the forefront of the allergy treatment landscape. The ability to demonstrate tangible, measurable outcomes—like the 15% increase in adherence or the dramatic boost in pediatric independence—gives healthcare providers and patients confidence in both the treatment and the technology supporting it.
the findings from the SPEED survey provide a robust platform for the broader adoption of iPUMP® across global markets. Stallergenes Greer plans to continue leveraging real-world data, patient feedback, and clinical insights to refine and expand the capabilities of its connected tools.
In presenting the SPEED survey results at CFA 2025, Stallergenes Greer is not only showcasing the success of a single product—it is illustrating a vision for the future of allergy care: one that is digital, individualized, and rooted in real-world impact.
